AAA-ICDR® Announces New Board Leadership and New Board Members to Advance the Strategic Transformation of ADR

39 minutes ago
GlobeNewswire

New Appointments Support Strategic Vision, Operational Strength, and Innovation in ADRNEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The American…

Orbit International Corp. Reports 2025 First Quarter Results

51 minutes ago

First Quarter 2025 Net Loss of $2,152,000 ($0.65 loss per share) v. Net Loss of $751,000 ($0.22 loss per share)…

Freight Technologies to Purchase Additional $1 Million of Official Trump Tokens

1 hour ago

-Company issues additional $1 million of convertible notes from existing $20 million facility--Continues advocacy for fair and free trade across…

CEO T.J. Rodgers Letter to SPWR Shareholders

1 hour ago

OREM, Utah, May 12, 2025 (GLOBE NEWSWIRE) -- T.J. Rodgers, the CEO of SunPower (aka Complete Solaria, Inc.) (“SunPower” or…

LM Funding America Announces April 2025 Production and Operational Update

1 hour ago

- Bitcoin HODL 148.7 BTC as of April 30, 2025 valued at $14.1 million or $2.75 per share1 TAMPA, Fla.,…

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

1 hour ago

Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) --…

The Six Five Summit: AI Unleashed 2025 Explores the Future of Artificial Intelligence

1 hour ago

Six Five Media introduces new event programming for its flagship annual Six Five Summit, unveils Show Opening Keynote Michael Dell…

Lincoln Educational Services Reports First Quarter Financial Results: Double Digit Growth in Revenue and Student Starts, Increased Outlook for Full Year 2025

2 hours ago

Conference Call Today at 10 a.m. Eastern Standard TimePARSIPPANY, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation…

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

2 hours ago

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of…

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

2 hours ago

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a…

This website uses cookies.